clinical trial · NCT02858908
Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy
Myotonic Dystrophy 1Tideglusib
brief summary
The purpose of this study is to determine whether Tideglusib is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy. The pharmacokinetics of tideglusib and its primary metabolite will also be investigated.
started
Jul 20, 2016
primary completion
Jan 1, 2018
completion
Jan 1, 2018
last updated
Sep 11, 2025
official title
A Single-Blind, Phase 2 Study To Evaluate The Safety And Efficacy Of Tideglusib 400mg Or 1000mg For The Treatment Of Adolescent And Adult Congenital And Juvenile-Onset Myotonic Dystrophy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol